Medopad raises £19.4m in Series B funding led by Leaps by Bayer for digital health expansion.
The Series B round was led by Leaps by Bayer to support clinical studies and technology development.
Medopad is a London-based health technology company that builds digital health platforms and remote patient monitoring tools for clinical research and care. It partners with healthcare systems and life science organisations to advance proactive medicine.
Medopad has secured £19.4m in a Series B funding round led by Leaps by Bayer. The capital will be directed towards clinical studies, technology development, international expansion, and commercial growth. The company provides a digital health platform that connects patients, clinicians, and researchers to support chronic disease management and clinical trials.
From the founder
"Medopad has a bold mission to help people live their life to the fullest – one that requires long-term commitment and partnership to achieve. We are delighted that Leaps by Bayer who participated in our Series A round have now become the lead investor in our Series B. We have found the ideal partner with the dedication to help us reach our vision of creating a world where each person lives their life to the fullest."
Dan Vahdat
Founder and CEO at Medopad
Use of funds
- 01Fund research and development
- 02Expand into international markets
- 03Accelerate go-to-market